NightHawk flies into national stockpile deal with Canadian government for anthrax drug
New name, new building, new deal.
NightHawk Biosciences, which was known as Heat Biologics until last week, has finalized a contract with the Canadian government to supply its anthrax treatment.
Anthim will be added to the country’s national stockpile for $7.9 million CAD. The deal will help bolster the supply of the inhalation anthrax treatment for the use against a potential biothreat.
NightHawk cited the CDC’s report that says if a bioterrorism attack were to happen, the bacteria that causes anthrax (bacillus anthracis) would be the most likely to be used, because the spores can be easily found in nature and produced in a lab.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.